Kyverna CFO Shakeup and 1,254% Volume Spike as GordonMD Grabs 19.4% Stake

Introduction

Kyverna Therapeutics Inc. (NASDAQ: KYTX) is a clinical-stage biopharmaceutical company headquartered in Emeryville, California. Incorporated in 2018, Kyverna develops chimeric antigen receptor (CAR) T-cell technology for the treatment of autoimmune diseases, focusing on deep B-cell depletion, immune system reset, and treatment-free remission.

Corporate Structure and Team

Kyverna employs a patient-centric model with active clinical trial sites across North America, Europe, and Asia. The company’s leadership includes Chief Executive Officer Warner Biddle and, as of June 30, 2025, Chief Financial Officer Marc Grasso, M.D., who has over 25 years of experience in capital markets and investment banking within the life sciences sector. Kyverna’s staff consists of scientists, clinicians, and support personnel collaborating within a hybrid work environment and benefiting from flexible paid time off, comprehensive medical coverage, and equity-based incentives.

CAR T-cell Therapy by Anton Darius

Recent Developments and News

On June 30, 2025, Kyverna appointed Dr. Marc Grasso as CFO, succeeding Ryan Jones, who transitioned to a strategic advisor role. On November 12, 2025, the company filed Form 10-Q for the quarter ended September 30, 2025, and concurrently submitted an 8-K disclosing material developments. On November 13, 2025, Kyverna hosted a webinar for the generalized myasthenia gravis (gMG) community to discuss its Phase 3 KYSA-6 trial of KYV-101. On November 17, 2025, a Schedule 13G filing revealed that three GordonMD entities collectively hold 8,530,051 shares—approximately 19.4% of outstanding stock.

Financial and Strategic Analysis

As of November 18, 2025, KYTX shares traded at $7.08, down 1.12% with a volume of 784,249 shares, compared to an average daily volume of 57,915 (a 1,254% increase). Kyverna’s pipeline includes:

• KYV-101, an autologous CD19 CAR T-cell therapy in registrational trials for stiff person syndrome and myasthenia gravis
• KYV-102, an autologous CD19 CAR T-cell candidate with rapid manufacturing in Phase 1
• KYV-201, an allogeneic CD19 CAR T-cell therapy under collaboration with Intellia Therapeutics

Kyverna aims to leverage the successes of CAR T therapies in hematological malignancies to address B-cell-driven autoimmune diseases. The license and collaboration agreement with Intellia supports its allogeneic development capabilities.

Market Position and Industry Context

Kyverna operates in a field where CAR T-cell therapies have demonstrated efficacy in B-cell malignancies but are still developing applications in autoimmune indications. Regulatory pathways and clinical trial outcomes will be essential for broader adoption. The company’s focus on single-infusion approaches aims to distinguish its candidates from chronic immunosuppressive regimens in treating conditions such as lupus nephritis, multiple sclerosis, and systemic sclerosis.

tl;dr

Kyverna appointed Marc Grasso, M.D., as CFO on June 30, 2025; GordonMD entities disclosed a 19.4% stake on November 17, 2025; and the Phase 3 KYSA-6 trial for KYV-101 in generalized myasthenia gravis is in progress following a November 13, 2025, webinar. The company remains focused on advancing its CAR T-cell pipeline and executing late-stage clinical programs in autoimmune diseases.